This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Indiana University. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Innovations of Zach Kaur in Insulin Research
Introduction
Zach Kaur is a notable inventor based in Bloomington, IN (US). He has made significant contributions to the field of insulin research, particularly through his innovative patent related to insulin analogs. His work focuses on enhancing the efficacy and specificity of insulin receptor interactions.
Latest Patents
Zach Kaur holds a patent titled "Single-chain insulin agonists exhibiting high activity at the insulin receptor." This patent describes single-chain insulin analogs that demonstrate high potency and specificity for the insulin receptor. The invention involves optimally sized linking moieties that connect human insulin A and B chains, or their analogs and derivatives. The linking moiety can include a polyethylene glycol of 6-16 monomer units or a non-native amino acid sequence derived from the IGF-1 C-peptide, comprising at least 8 and no more than 12 amino acids in length. Additionally, the patent discloses prodrug and conjugate derivatives of these single-chain insulin analogs.
Career Highlights
Zach Kaur is affiliated with Indiana University, where he continues to advance his research in insulin analogs. His work has the potential to significantly impact diabetes treatment and management. With a focus on innovative solutions, he is dedicated to improving the lives of individuals who rely on insulin therapy.
Collaborations
Zach collaborates with esteemed colleagues such as Richard Dennis DiMarchi and Julia Azriel. Their combined expertise fosters a productive research environment that encourages groundbreaking discoveries in the field of insulin research.
Conclusion
Zach Kaur's contributions to insulin research through his innovative patent highlight his commitment to advancing medical science. His work not only enhances our understanding of insulin receptor interactions but also paves the way for improved therapeutic options for diabetes patients.